Haddad, R., Guigay, J., Keilholz, U., Clement, P. M., Fayette, J., de Souza Viana, L., Rolland, F., Cupissol, D., Geoffrois, L., Kornek, G., Licitra, L., Melichar, B., Ribaldo Nicolau, U., Rauch, D., Zanetta-Devauges, S., Cohen, E. E., Machiels, J., Tahara, M., Vermorken, J., Geng, Y., Zografos, E., & Gauler, T. (2019). afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral oncology, 97, 82–91. http://access.bl.uk/ark:/81055/vdc_100091292250.0x00000c